

# Cochrane Dementia and Cognitive Improvement Group

<https://neurodegenerationresearch.eu/survey/cochrane-dementia-and-cognitive-improvement-group/>

## Principal Investigators

McShane, Rupert

## Institution

University of Oxford

## Contact information of lead PI

### Country

United Kingdom

## Title of project or programme

Cochrane Dementia and Cognitive Improvement Group

## Source of funding information

NIHR

## Total sum awarded (Euro)

€ 890,528

## Start date of award

01/04/2015

## Total duration of award in years

5.0

## The project/programme is most relevant to:

Alzheimer's disease & other dementias|Parkinson's disease & PD-related disorders

## Keywords

### Research Abstract

Prevention, treatment, and management of acute or chronic acquired cognitive impairments, their manifestations and complications, and the care of people affected. Our remit includes both global cognitive impairment and focal cognitive impairments occurring in the context of brain disease such as Alzheimer's disease, vascular dementia, fronto-temporal dementias including Pick's disease, dementia with Lewy bodies and the spongiform encephalopathies. It also

extends to delirium, and to non-specific and age-associated cognitive impairments. We are concerned, in collaboration with other relevant Cochrane Groups, with cognitive impairment occurring as a complication of diseases such as diabetes, stroke and hypertension. Dementia with Parkinson's disease and in HIV disease are usually dealt with by the primary disease Groups. Single and complex interventions of all kinds are reviewed, including pharmacological, psychological, environmental, organizational, and alternative or complementary. All relevant outcomes are considered including changes in cognitive function, behaviour, activities of daily living, global clinical impression, dependency, carer burden, quality of life, use of resources, survival and institutionalization. Where suitable data are available, cost-effectiveness comparisons will be included in reviews. Interventions, pharmacological or otherwise, aimed at enhancing cognitive performance in normal people.

## **Lay Summary**

**Further information available at:**

### **Types:**

Investments > €500k

### **Member States:**

United Kingdom

### **Diseases:**

Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders

### **Years:**

2016

### **Database Categories:**

N/A

### **Database Tags:**

N/A